Ottmar Janssen - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Ottmar Janssen

Showing results (71-80 of 75) with videos related to

Pageof 8

Sort By:

You have reached the last page of results.This site can display upto 75 results.

Oncoimmunology|November 18, 2017

In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatmentGuranda Chitadze, Charlotte Flüh, Elgar Susanne Quabius, et al.

Chemistry & Biology|September 25, 2012

The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2Gernot Polier, Jennifer Neumann, Frédéric Thuaud, et al.

Frontiers in Immunology|February 23, 2026

Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from <i>in vitro</i> assaysMiriam Kelm, Nourhan Nasr, Sonja Bendig, et al.

Journal of Extracellular Vesicles|July 6, 2023

Chemotherapy-induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancerGerrit Hugendieck, Marcus Lettau, Svenja Andreas, et al.

Gastroenterology|October 15, 2013

Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cellsVerena Haselmann, Alexandra Kurz, Uwe Bertsch, et al.

Pageof 8

Search research articles

Showing results (71-80 of 75) with videos related to

Sort By:

Pageof 8

You have reached the last page of results.This site can display upto 75 results.

Oncoimmunology|November 18, 2017

In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatmentGuranda Chitadze, Charlotte Flüh, Elgar Susanne Quabius, et al.

Chemistry & Biology|September 25, 2012

The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2Gernot Polier, Jennifer Neumann, Frédéric Thuaud, et al.

Frontiers in Immunology|February 23, 2026

Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from <i>in vitro</i> assaysMiriam Kelm, Nourhan Nasr, Sonja Bendig, et al.

Journal of Extracellular Vesicles|July 6, 2023

Chemotherapy-induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancerGerrit Hugendieck, Marcus Lettau, Svenja Andreas, et al.

Gastroenterology|October 15, 2013

Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cellsVerena Haselmann, Alexandra Kurz, Uwe Bertsch, et al.

Pageof 8